SynthesisHepatology international2017
Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
Zilin Tang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this paperpooled ittrialcites it